Acute myeloid leukemia, IDH-mutated

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 13:18, 25 January 2018 by Dryang (talk | contribs) (Text replacement - "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:300%"> Just 8 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br>  '''Link:''' http://j.mp/2BlBaoQ </span> |}" to "{{:Editing test page 2}}")
Jump to navigation Jump to search

Carboplatin & Paclitaxel (CP)

CP: Carboplatin & Paclitaxel

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Forde et al. 2022 (CheckMate 816) 2017-2019 Phase 3 (C) 1a. CP & Nivolumab
1b. CVb & Nivolumab
1c. DC & Nivolumab 		Inferior EFS

Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details. This study was conducted in the United States. The reason for the study was that an unanswered question at the time was whether adding an immune checkpoint inhibitor would improve outcomes.

Biomarker eligibility criteria

  • CheckMate 816: No sensitizing EGFR or ALK mutations

Chemotherapy

21-day cycle for 3 cycles

Subsequent treatment

References

  1. CheckMate 816: Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. Epub 2022 Apr 11. link to original article contains dosing details in manuscript PubMed NCT02998528

Start of hidden/commented information for virtual editor End of hidden/commented information for virtual editor



Start of comment inserted by visual editor(edited again by visual editor)

(edited again by visual editor end)End of comment inserted by visual editor
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Note: these are biomarker-specific regimens for patients with IDH1 or IDH2-mutated AML, please see the main AML page for other regimens.

8 regimens on this page
8 variants on this page


Relapsed or refractory, salvage therapy

Enasidenib monotherapy

back to top

Regimen

Study Evidence ORR
Stein et al. 2017 Phase I/II 40%

This is the dose used in the expansion cohort; enrolled patients were required to have IDH2-mutated advanced myeloid malignancies.

Chemotherapy

28-day cycles

References

  1. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722-731. Epub 2017 Jun 6. link to original article contains verified protocol link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Acute_myeloid_leukemia,_IDH-mutated&oldid=23591"